Table 1.
Demographic and clinical characteristics of patients diagnosed with asthma (n= 54)
| Patients with asthma | |
|---|---|
| Age | |
| Age, yr, median (IQR) | 10.5 (7–15) |
| Age at diagnosis of asthma, yr, median (IQR) | 4 (1–9) |
| Gender (female/male) | 0.86 |
| Male, n (%) | 29 (53.7) |
| Concomitant allergic diseases, n (%) | 17 (31.5) |
| Allergic rhinitis | 13 (24.1) |
| Food allergy | 3 (5.6) |
| Atopic dermatitis | 1 (1.9) |
| Chronic urticaria | 1 (1.9) |
| Family member having allergic disease, n (%) | 14 (25.9) |
| Atopy status, n (%) | |
| Aeroallergen sensitization | 18 (33.3) |
| Pollen | 12 (22.2) |
| House dust mite | 7 (13) |
| Mold | 2 (3.7) |
| Cat and dog dander | 3 (5.6) |
| Cockroach | 1 (1.9) |
| Used asthma maintenance therapy before COVID-19, n (%) | |
| Patients used asthma medications | 23 (42.7) |
| Only using ICS | 11 (20.4) |
| Only using antileukotrienes | 5 (9.3) |
| Both using ICS and antileukotrienes | 6 (11.1) |
| Both using ICS and LABA | 1 (1.9) |
| Admission to clinic control during pandemic, n (%) | |
| Patients admitted to control for asthma | 14 (25.9) |
| Asthma control, n (%) | |
| GINA assessment of asthma in the last 3 mo (n:46) | |
| Well controlled | 36 (66.7) |
| Partly controlled | 5 (9.3) |
| Uncontrolled | 5 (9.3) |
| Patients having asthma attack in the last 1 yr | 2 (3.7) |
IQR, interquartile range; ICS, inhaled corticosteroids.